Amy W. Schulman

Amy W. Schulman joined Harvard Business School’s Faculty as a Senior Lecturer in July 2014.

In addition to her responsibilities at Harvard, Ms. Schulman is a managing partner at Polaris Partners, who focuses on investing in healthcare companies and early-stage biotech start-ups. For the past twenty-five years, she has been a leader in healthcare -- first as a global law firm senior partner and the general counsel of a Fortune 50 pharmaceutical company, then as president of that company's consumer products and nutrition divisions, and more recently as a biotech entrepreneur with deep relationships in the US, Singapore and other Asian markets -- whose business acumen, regulatory experience and interpersonal engagement have driven positive change for countless patients, providers, companies, and investors.

Ms. Schulman serves as chair of the Board of Directors of Alnylam Pharmaceuticals (NASDAQ: ALNY) and as chair of the Board of Directors of ByHeart and is on the boards of Fractyl Health (NASDAQ: GUTS) and ClavystBio.
 
Ms. Schulman also serves on the Boards of the California Institute of Technology, Mount Sinai Hospital, and Action Against Hunger. She is an appointed member of Singapore’s Health and Biomedical Sciences International Advisory Council and serves on several quasi-government boards in Singapore.
 
Ms. Schulman has received numerous awards, including the Margaret Brent Women Lawyers of Achievement Award, Scientific American’s Worldview 100 List, Fierce Biotech’s Top 15 Women in Biotech, and Fortune Magazine’s 50 Most Powerful Women in Business.
 
She is a graduate of Wesleyan University and Yale Law School.